A threesome so nice, we did it twice: talking $BMYRT with Matt and Dan (again)
About this episode
Our first threesome was such a success, we decided to do it again! Dan and Matt come back on to discuss all of the updates on the BMY CVR since our first post; in particular, we discuss Dan's due diligence that suggests an FDA inspection is on going.
PS- CVR's are risky and nothing on here is investing advice.
You can find our first threesome here: https://twitter.com/AndrewRangeley/status/1305835912975261697?s=20
My updated take on the CVR here: https://yetanothervalueblog.com/2020/10/bmy-cvr-an-inspection-inflection-bmyrt.html
Twitter handles:
Matt: Given2Tweet (https://twitter.com/given2tweet)
Dan: Sheep of Wall Street (https://twitter.com/Biohazard3737)
Get every episode summarized
Each time Yet Another Value Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Yet Another Value Podcast
UK stocks are dirt cheap. Why won't the boards act? $ZIG $CRW | Undervalued-Shar...
Yet Another Value Podcast
Zack Buckley on $PRTH's take private
Yet Another Value Podcast
$TBBB: Tiendas 3B is Mexico's Aldi. Is it too late to buy? | Fruit Tree Capital
Yet Another Value Podcast
$LMB: Limbach missed the data center boom. Is that the opportunity? | 1 Main Cap...
Yet Another Value Podcast